Vilon
/ Khavinson-tradition dipeptide (Lys-Glu); proposed thymus / immunomodulating bioregulatorALIAS · KE · Lys-Glu · Thymic dipeptide
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Vilon is the trade designation for the synthetic dipeptide Lys-Glu (KE), proposed in the Khavinson school as a thymic / immunomodulating peptide bioregulator. KE is the shortest member of the Khavinson tripeptide and dipeptide family and has been the subject of multiple Russian primary publications on rodent lifespan, age-related immune restoration, and cell-culture transcription effects; independent Western replication is limited.
Within the Khavinson programme, KE is positioned as a thymic peptide bioregulator restoring age-related declines in T-cell maturation and immune function. Cell-culture and rodent work from the originating laboratory describes effects on thymocyte differentiation markers, cytokine secretion patterns, and (in long-term rodent administration studies) lifespan extension. The mechanistic framework invokes the same direct-DNA-binding transcription-modulation hypothesis as the broader Khavinson peptide-bioregulator literature.
Tier 4. Russian-language primary literature includes rodent lifespan studies and small clinical-tradition reports in age-related immunosuppression. PubMed-indexed Western replication is sparse. No Phase 1 or later trial in Western literature.
No formal Phase 1 human safety database in Western literature. Russian clinical tradition reports good tolerability.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature without independent Western replication. The lifespan-extension claims for KE in rodents are central to the Khavinson programme's case for bioregulator significance and have not been reproduced by independent groups under contemporary methodology. Vendor-sold KE is a chemically defined dipeptide; the pharmacological positioning is inherited from an unreplicated literature.